Community/Retail

Officials with the FDA have approved plecanatide (Trulance, Synergy) for the once-daily treatment of irritable bowel syndrome with constipation (IBS-C) in adults.

Officials with the FDA have issued 2 final guidance documents to help implement the 2018 Compounding Policy Priorities Plan, which explain the agency’s policies on the “essentially a copy” provisions of sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.